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Background. The probability of reimbursement is a key fac-
tor in determining whether to proceed with or abandon a 
product during its development. The purpose of this article 
is to illustrate how the methods of iterative Bayesian eco-
nomic evaluation proposed in the literature can be incorpo-
rated into the development process of new medical devices, 
adapting them to face the relative scarcity of data and time 
that characterizes the process. Methods. A 3-stage eco-
nomic evaluation was applied: an early phase in which 
simple methods allow for a quick prioritization of compet-
ing products; a mid-stage in which developers synthesize 
the data into a decision model, identify the parameters for 
which more information is most valuable, and explore 
uncertainty; and a late stage, in which all relevant informa-
tion is synthesized. A retrospective analysis was conducted 
of the case study of absorbable pins, compared with metallic 
fixation, in osteotomy to treat hallux valgus. Results. The 
results from the early analysis suggest absorbable pins to be 
cost-effective under the beliefs and assumptions applied. 
The outputs from the models at the mid-stage analyses 
show the device to be cost-effective with a high probability. 
Late-stage analysis synthesizes evidence from a random-
ized controlled trial and informative priors, which are 
based on previous evidence. It also suggests that absorbable 
pins are the most cost-effective strategy, although the 
 uncertainty in the model output increased considerably. 
Conclusions. This example illustrates how the method pro-
posed allows decisions in the product development cycle to 
be based on the best knowledge that is available at each 
stage. Key words: cost utility analysis; evidence synthesis; 
Bayesian meta-analysis; priority setting for spending; ortho-
pedics. (Med Decis Making 2011;31:596–610)
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Some health care systems such as the National Health Service (NHS) in the United Kingdom 
increasingly make reimbursement decisions based 
on both clinical and cost-effectiveness evidence of 
new therapies compared with standard care or alter-
native technologies. To this end, guidelines for tech-
nology appraisals have been developed by the National 
Institute for Health and Clinical Excellence (NICE).1 In 
recognition of the inevitable uncertainty surrounding 
the measurement of costs and effectiveness of differ-
ent strategies, the guidelines emphasize the use of 
methods that quantify the implications of parameter 
and methodological uncertainty for the results as well 
as methods that assess the value of conducting further 
research to reduce the uncertainty relating to the reim-
bursement decision. Therefore, methods such as 
 probabilistic sensitivity analysis (PSA) and value-of-
information (VOI) analyses are now increasingly 
incorporated into economic evaluations. 
Recently, the potential value and practicality of 
incorporating Bayesian methods into the iterative 
framework of health technology assessment (HTA) 
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have been described.2 This builds on the idea that 
reimbursement decisions may be reviewed on the 
basis of new evidence that becomes available in the 
life cycle of a technology.3 The Bayesian approach is 
ideal for this since it facilitates combining prior 
information with more recent data to inform whether 
the technology appears cost-effective after all avail-
able information has been incorporated. 
The iterative Bayesian approach to HTA can also 
be applied within the commercial or government-
funded development of new products. The develop-
ment cycle of new technologies often takes the form 
of a staged-decision making process that is regularly 
reviewed and in which decisions of whether to pro-
ceed with the innovation are made at several differ-
ent time points.4 Incorporating economic evaluations 
into such a stage-gated decision process from very 
early stages of the development could support inter-
nal investment decisions in order to prioritize poten-
tial products or prototypes to take forward and may 
avoid investing in technology that could never be 
cost-effective. In addition, given that at the develop-
ment stage there is still scope for further research 
before the product is brought to market, formal 
analysis that aims to identify the parameters with the 
largest impact on the likely cost-effectiveness could 
direct internal research resources more  efficiently. 
In many cases data are scarce and the time to per-
form the analysis is likely to be short, particularly in 
the medical device industry, compared with those late-
stage public sector evaluations for which the iterative 
Bayesian approach has been illustrated.2 At early 
stages, a potentially large number of products in com-
peting lines of development would need to be evalu-
ated. Therefore, the methods need to be adapted to 
avoid undue delay in the innovative development 
process. To address these issues we propose starting 
with relatively simple economic evaluations at the 
very early stages that would provide a rapid indication 
of potential cost-effectiveness and then increasing the 
depth of analysis in later stages as more information 
becomes available and attention is centered on fewer 
products. The principal aim of the approach is to 
ensure that early-stage evaluations can be internally 
undertaken within the resources of even small medi-
cal device firms. This is not, however, intended to be 
a substitute for more sophisticated modeling where 
that is practical but it is intended as a way to ensure 
that informed decisions are made in all situations.
To illustrate the approach, we applied this method 
retrospectively to the case study of absorbable pins 
in osteotomy to treat hallux valgus. We evaluate 
what was known about the cost-effectiveness of this 
fixation device compared with standard fixation 
methods from a very early stage of the development 
of the device, iteratively incorporating further infor-
mation as it became available at later stages. At each 
step of the evaluation we explore the uncertainty of 
the decision and the parameters for which the model 
outcome is most sensitive. 
The case study was based on the use of absorbable 
pins in the treatment of hallux valgus. Hallux valgus 
is defined as a deviation of the big toe (hallux) 
toward the midline of the foot. When the condition 
is first diagnosed, conservative treatment such as 
orthosis, night splints, or foot exercise may be 
attempted. Alternatively, surgical procedures are 
used when the deformity makes fitting footwear a 
problem or when the foot function is affected and 
the joint becomes painful. The most common proce-
dure is the metatarsal osteotomy, where the bone is 
divided surgically and repositioned. There are dif-
ferent methods to stabilize the osteotomy while the 
bone unites: bone suture, internal metallic fixation, 
and a more recent method, absorbable pins.
METHODS
To illustrate the approach, we consider the case of 
a company that was developing an absorbable device 
and planning to sell it for use in osteotomies to treat 
hallux valgus (Orthosorb; Johnson & Johnson, New 
Brunswick, New Jersey). The stage gates for this 
project are based on the following timeline: gate 1, 
the company received approval for conducting clin-
ical trials in 1987 based on a comparison with simi-
lar products; gate 2, in 1990 a competitor product 
entered the market; gate 3, the product received 
CE-Mark approval in 1995 (CE stands for Conformité 
Européenne and certifies that a product has met EU 
consumer safety, health, or environmental require-
ments); gate 4, from 1995, a series of postmarketing 
studies were conducted.
We apply a previously published5 3-stage eco-
nomic evaluation approach as summarized in Figure 
1. At each gate, economic evaluations are carried out 
using the information available at that time. A litera-
ture search was undertaken for each time period, and 
the articles identified for each analysis are reported in 
the appendix. The evaluation methods used vary in 
their complexity and the time required to conduct 
them, and different types of economic evaluation 
methods could be used at the same point in time to 
evaluate the product if needed. Early-stage analysis is 
conducted using the information prior to 1987 (gate 
1). Subject to the results from the analysis a company 
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could decide to proceed with the device and under-
take a more formal evaluation. Therefore, mid-stage 
analyses that synthesize the data into a decision 
model are also conducted at gate 1. Such a model 
provides an ideal framework to update the results 
when new evidence becomes available in 1990 and 
1995 (gate 2 and 3). At the late-stage analysis applied 
post 1995 (gate 4), the information collected previ-
ously is used to form prior distributions of parameters 
that are then updated with the findings from a ran-
domized controlled trial (RCT) available at this stage. 
Uncertainty is explored at the mid- and late-stage 
analyses. In the mid-stage analyses, all parameters 
were subjected to 1-way sensitivity analyses apply-
ing wide test ranges. In the decision-analytic mod-
els, PSA is undertaken by applying probability 
distributions to each parameter of the model and 
running 5000 iterations in the simulation. For com-
pleteness, value of information analyses are pre-
sented at each gate, although they are most relevant 
at the late-stage evaluation, which is aimed at 
informing external decision makers concerned with 
the societal perspective that underpins the VOI 
approach. In these analyses, the expected value of 
perfect information is calculated by estimating the 
number of operations in the United Kingdom over 
an assumed lifetime of the technology of 5 years, 
herewith accounting for the relatively short lifetime 
of medical devices compared with drugs or other 
medical technologies. 
Early-Stage Analysis 
A company or government agency would conduct 
this analysis at the phase in the development when 
the product may still be just an idea or a concept and 
when a potentially large number of alternative tech-
nology developments are competing for research and 
development resources. At this stage similar analyses 
would be undertaken for other products in competing 
lines of development. These analyses would be con-
ducted under optimistic assumptions, making the tool 
quite sensitive for the detection of worthwhile ideas. 
However, these analyses can only be considered as 
indicative as they do not account for uncertainty. 
Recent work has focused on extending these methods 
to allow for uncertainty in early-stage valuations.6 
Methods
The first step is to identify the potential areas of 
improvement that the new device will have over the 
current technology (in terms of both cost savings and 
increased effectiveness) and estimate its monetary 
value. In the absence of data about the new technol-
ogy, the analysis is based on the evidence concern-
ing the current technology that the new product 
aims to substitute or will compete with, plus expert 
opinion and/or assumptions regarding the impact on 
cost and effectiveness of the new technology. The 
data are then analyzed using simple techniques 
based on the “effectiveness gap,”7 which estimates 
the extent to which current practice is less than 
totally effective, or the “headroom method,”8 which 
is based on the maximum additional cost of the new 
treatment over the comparator that has been pro-
posed to establish a price ceiling. These methods 
will therefore provide bounds on the maximum 
reimbursable price that will then be compared with 
the expected cost of the device at this stage. 
Data
Before 1987, there was evidence of the successful 
use of synthetic absorbable materials for suturing 
and fracture fixation in malleolar fractures9,10 and 
some promising results in distal femoral osteotomies 
in trials with rabbits.11 However, no clinical evi-
dence for its use in hallux valgus operations had yet 
Gates Data Methods
Gate 1 (… -1987) Observational data on standard
methods + assumptions
Headroom/Effectiveness gap method
Mid-stage Observational data on standard methods
& absorbable pins + assumptions
Decision model (deterministic and
probabilistic) + one-way SA
Gate 4 (1996 -…) RCT + observational data on standard
methods and absorbable pins
Decision model (deterministic and
probabilistic) + VOI analysis
Note: RCT: Randomised Control trial; SA: Sensitivity Analysis; VOI: Value of Information
Early-stage
Late-stage
Gate 1 (… -1987)
Gate 2 (1988-1990)
Gate 3 (1991-1995)
Figure 1 Stage-gates for iterative analysis of cost-effectiveness of absorbable pins. 
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been reported. Therefore, the evaluation at this stage 
is based on the data available on metallic devices 
and expert opinion and assumptions regarding the 
impact of the new device on cost and effectiveness. 
Probabilities. Metallic fixation with a screw or 
percutaneous K-wire often requires removal at a 
later date and also carries a risk of refracture and 
infection. Theoretically, absorbable pins obviate 
removal surgery because they decompose gradually 
and the stress is transferred gradually to the healing 
tissue. It was thus assumed that absorbable devices 
would reduce the probability of stress fracture and 
wound infection by half compared with metallic 
devices and that they would completely avoid the 
need for removal surgery. The probabilities of these 
events after a metallic fixation were taken from the 
literature and are reported in Table 1. 
Costs. Early-stage cost data reported in UK pounds 
(Table 1) were taken from the NHS Reference Cost 
2006–200712 and deflated to 1987 (this data set had 
not been developed in the earlier years of the analy-
ses; however, as the aim of this case study is to illus-
trate the method that one would use to assess 
cost-effectiveness of technologies now being devel-
oped and the data is now routinely available, it is 
used in each stage).
Quality of life. The predicted impact of the new 
technology on quality of life (QoL) was elicited from 
a group of manufacturers with experience with the 
standard and with the innovative devices to inform 
early analyses. This was a fairly crude elicitation 
exercise where a group of experts (n = 5) were asked 
to estimate the mean, minimum, and maximum 
quality-adjusted life year (QALY) weight (scale 0–1) 
for each strategy (i.e., absorbable pins and standard 
fixation). Given the retrospective nature of our anal-
ysis, these views represent the expectations of man-
ufacturers at the time of development.
Results
Table 1 presents the results for the early-stage 
analysis. The assumptions applied on the risks of 
refracture, infection, and removal led to a cost saving 
of £465 per procedure compared with metallic 
devices. The elicited estimates of the QALY weights 
after treatment were 0.90 for metallic pins and 0.95 
for absorbable pins. The difference was possibly 
attributable to increased stability, which decreases 
the risk of displacement and subsequent metatarsal-
gia (pain) and was assumed to last for the lifetime of 
the patient. Therefore, this provided an estimate of 
the incremental QALY of (0.95 – 0.90) = 0.05 per 
year; which given a £20 000 per QALY potential cost-
effectiveness threshold translates into £20 000 * 0.05 
= £1000 per year. Individuals in the studies reviewed 
were mainly female (around 90%) and the mean age 
was 40 years. Considering a life expectancy of 38 
years and discounted at 3.5%, the expected (dis-
counted) benefit is £20 841 assuming that the effect 
lasts the remaining life expectancy of the individu-
als. The overall headroom estimate of the maximum 
reimbursable price is £21 306 (£465 + £20 841).
This sort of analysis would inform a company or 
government agency at an early stage of development 
that if absorbable pins were to have the effect on 
QoL believed by experts, then they would be cost-
effective even if the incremental price of the device 
was very high (up to £21 306). Once the company 
estimates the potential cost of the new technology, 
this can help to prioritize resources in order to avoid 
proceeding with products that will never be more 
than marginally cost-effective. In the case study, the 
headroom estimate was far higher than the expected 
incremental cost of the technology (even with a gen-
erous allowance for the cost of development), and 
therefore the company, given this estimation, may 
decide to proceed in terms of the cost-effectiveness 
of the product. 
Table 1 Early-Stage Analysis: Data and Result
Metallic Absorbable
Probability of 
 Removal 1.0a 0.0a
 Fracture 0.010b 0.005a
 Infection 0.044c 0.022a
Cost of
 Removal £464e
 Fracture £49f
 Infection £49f
Cost saving £465
Elicited quality of life 0.90d 0.95d
Overall headroom estimate £21 306
Sources (Bayesian random-effect meta-analysis, when more than 1 
source of data, from articles reported in the appendix)
a. Assumption: All metallic pins need removal, and the risks of fracture 
and infection after absorbable fixation are assumed to be half of those 
when using metallic pin.
b. [9].
c. [2,3,9].
d. Expert opinion.
e. National Health Service (NHS) reference cost, minor foot procedure for 
nontrauma category 2 without complications and comorbidities (CC).
f. NHS reference cost, minor foot procedure for nontrauma category 2 
with CC—NHS reference cost, minor foot procedure for nontrauma 
category 2 without CC.
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Mid-Stage Analysis
At a mid-stage, typically, observational studies 
may provide some clinical evidence of the effect of 
the new technology, and some initial cost estimates 
may be available. Under these conditions, decision-
analytical modeling techniques can be applied and 
the uncertainty in the decision can be explored. We 
apply these methods to explore the decision at gate 
1 (i.e., we re-run more formally the analysis previ-
ously undertaken using the early-stage techniques). 
This requires incorporating more information in 
order to populate the decision model. We then 
update the analysis with the information available 
in 1990 and 1995 (i.e., gate 2 and gate 3). 
Methods
We synthesize the data available in a decision-
analytic model that takes the form of a decision tree. 
The model structure is presented in Figure 2. For 
each method of fixation, the tree represents the path-
ways that the patients may follow. After the surgery, 
a patient undergoing an osteotomy may heal with no 
complications, may need revision surgery, or may 
suffer from other types of complications that do not 
require a new surgical procedure. Once the patient 
is healed, and depending on the type of fixation, 
some patients require surgery to remove the fixation 
device, after which the condition may be satisfacto-
rily cured or may reoccur.
Two important issues are addressed at this stage: 
1) synthesizing the evidence available, and 2) explor-
ing the uncertainty around the parameters in the 
model in order to find the inputs with the largest 
impact on the model outcome. Synthesizing the evi-
dence available may require combining evidence 
from multiple sources of data, and using formal 
Bayesian evidence synthesis techniques will ensure 
that the uncertainty is incorporated appropriately.13 
When pooling data we use Bayesian meta-analysis 
models that allow for between-study variation with 
vague priors for the mean and variance of the study-
specific effect sizes. 
To assess the second issue of identifying the key 
parameters affecting the cost-effectiveness, we sug-
gest starting with simple 1-way sensitivity analysis, 
where each relevant parameter is varied one at a 
time to study its impact. These methods are easy and 
quick to undertake and to understand, and they pro-
vide some insight into alternative values for specific 
parameters that could make a meaningful impact on 
the model outcome and on the potential decision 
based upon it. However, they have been criticized 
for not being able to account for the overall uncer-
tainty from the combined variability of several fac-
tors.14 This uncertainty can be explored via PSA. In 
PSA, probability distributions are applied to the 
parameters and samples are randomly drawn from 
these distributions using simulation techniques. 
Results can then be represented using cost-effective-
ness acceptability curves (CEACs), which show the 
probability that a given intervention is the most cost-
effective strategy at different values of willingness-
to-pay for a unit of effect by future potential health 
care purchasers. PSA results can also be used to 
quantify the societal cost of making the wrong deci-
sion about which technology to fund. This repre-
sents the expected value of perfect information 
(EVPI). In addition, the EVPI can be computed for 
various sets of parameters to inform the specific con-
sequences of the technology (e.g., impact on cost, 
utilities, or health status) for which more informa-
tion is most valuable. This is referred to as expected 
value of perfect partial information (EVPPI). Note 
that this standard VOI analysis is related to a collec-
tive view of the value of this additional research for 
the society, both in terms of forgone health gain to 
patients and in terms of wasted resources, and there-
fore would not be directly relevant in a commercial 
context. Thus, this analysis, although conducted at 
each gate, is only considered relevant in the final 
stage, which is aimed to inform external decision 
makers concerned with collective welfare.
Data
Data for the mid-stage analyses are summarized in 
columns 1–3 of Table 2 and Table 3. 
Cured
Healed Removal
Reoccur
Cured
Healed
Reoccur
Revision
Cured
Removal
Reoccur
Cured
Other complications Reoccur
Osteotomy
Absorbable fixation
Metallic fixation
Suture fixation
Other complications
Removal
Figure 2 Simple decision tree for fixation methods.
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Probabilities. Data on the probability of any event 
after the surgery were taken from the literature and 
synthesized using WinBUGS (Windows-based 
Bayesian inference using Gibbs sampling). Uninfor-
mative prior distributions were used, and the data 
were synthesized using Bayesian random-effects 
meta-analyses. 
Before 1991 there was no formal data on the use 
of absorbable pins, although data on probabilities 
after the use of metallic devices and sutures were 
available. The probabilities for absorbable devices 
were assumed to be the same as those for metallic, 
with the exception of the risk of fracture and infec-
tion, for which we applied the same assumption as 
in the early-stage analysis (i.e., we assumed these 
probabilities to be half of those when using metallic 
devices). To incorporate the uncertainty of those 
assumptions in the probabilistic analysis, we applied 
odd ratios (ORs) to ensure that the probabilities lay 
between zero and one. 
In 1995, a number of observational studies pro-
vided evidence for the prognosis of patients treated 
surgically for hallux valgus with absorbable devices, 
and these data were used in the decision tree and 
summarized in Table 2. However, the use of sutures 
as a fixation method is no longer reported; therefore, 
in this evaluation period, absorbable pins were only 
compared with metallic fixation.
We assumed that all metallic devices need to be 
removed (which corresponds to what is reported in 
the early literature, mainly because of the frequent use 
of percutaneous K-wires), whereas only 2% of sutures 
and absorbable devices require removal surgery.
Costs. We applied the costs from NHS reference 
costs data deflated to the year of interest (Table 3). 
The estimated cost of absorbable devices was pro-
vided by the company. We could not find contempo-
rary published data on the cost of standard fixation 
methods for the early years of the analysis. Therefore, 
we used the price as published in 199715 for metallic 
pins, deflated this to the year of interest, and assumed 
this to be the same for suture fixation devices (in 
reality, however, a company is likely to have or be 
able to obtain information regarding the cost of the 
standard technology being used). Gamma distribu-
tions were applied to all cost estimates in the proba-
bilistic sensitivity analysis, with their standard 
errors equal to the point estimate in the absence of 
further information. 
Quality of life. Before 1991, there were no data 
on health-related QoL relative to hallux valgus, but 
Table 3 Cost and Quality of Life Data for Mid-Stage and Late-Stage Analyses
Mid-Stage Analyses Late-Stage Analyses
Gate 1 (1987 and Earlier) Gate 2 (1988–1990) Gate 3 (1991–1995) Gate 4 (1996 Onward)
Costs
Procedurea £889 £1039 £1383 £1543
Complicationsb £49 £57 £76 £84
Revisionc £464 £542 £722 £805
Removalc £464 £542 £722 £805
Absorbable pinsd £63 £74 £98 £140
Metallic/suturese £4 £4 £6 £7
Reoccurrencef — — — £74
Quality of life
Successful surgery 0.981g 0.981g 0.986h 0.929i
Reoccurrence 0.916g 0.916g 0.956h 0.907i
Impact on QoL OR decrement (sx) 0.474
j (0.567) 0.474j (0.567) 0.474j (0.567) 1 (0.567)
Sources (from articles reported in the appendix): 
Note: OR, odds ratio; QoL, quality of life.
a. NHS reference cost, minor foot procedure for nontrauma category 2 without complications and comorbidities (CC). 
b. NHS reference cost, minor foot procedure for nontrauma category 2 with CC—NHS reference cost, minor foot procedure for nontrauma category 2 
without CC. 
c. NHS reference cost, minor foot procedure for nontrauma category 2 without CC, day case. 
d. Industry. 
e. [37]. 
f. [38]. 
g. [2].
h. [35].
i. [38].
j. expert opinion based on a QALY weight of 0.90 for metallic pins and 0.95 for absorbable pins. 
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estimates of pain and functioning were reported 
before and after the surgery16 and we mapped these 
to QALYs using SF-6D valuations (see Table 4). For 
this purpose, the level for the pain, physical func-
tioning, and role limitations dimensions (i.e., 
assumes no limitation for all other dimensions) was 
chosen according to the description of state, and 
then the utility was calculated. The severity catego-
ries were 1) no limitation, 2) mild pain and no func-
tional limitation, 3) moderate pain and occasional 
functional limitation, and 4) severe pain and fre-
quent functional limitation. The proportion of 
patients in each severity category was then used to 
estimate the overall QALY weight experience by 
patients before and after the surgery. We applied the 
estimated QALY weight before the surgery to indi-
viduals for whom the condition reoccurs after the 
surgical intervention. When propagating the uncer-
tainty, the proportion of patients in each severity 
category was computed using a Dirichlet distribu-
tion. At later stages, data on health-related QoL for 
individuals undergoing these procedures were avail-
able (see Table 3). We then applied beta distributions 
to the QoL weights in the probabilistic analyses. 
Based on an elicited QALY weight of 0.90 for 
metallic pins and 0.95 following successful surgery 
after using an absorbable device, the QoL “decre-
ment odds ratio” (difference from perfect health) 
was estimated to be 0.474 (i.e., [0.05/0.95]/[0.1/0.9]).
We applied the formula of the decrement OR to the 
QALY weight of the cured state when absorbable 
devices are used. A log normal distribution was 
applied in the probabilistic analysis for this param-
eter. QALYs were computed for a life expectancy of 
38 years and discounted at 3.5% per annum.
 
Results 
The deterministic results for each gate are shown 
in Table 5. We report the estimated expected 
cost and expected QALY for each strategy and the 
incremental cost-effectiveness ratio (ICER) presented 
as comparisons of each strategy to the next less 
effective strategy after dominated strategies have 
been discarded. The use of absorbable pins led to 
better expected health outcomes compared with 
both sutures and metallic fixation, and the overall 
expected cost was lower than that of metallic fixa-
tion and slightly more expensive than using sutures. 
The ICER of absorbable pins versus suture fixation 
was £356 per QALY in both 1987 and 1990, whereas 
absorbable devices were found to dominate metallic 
fixation methods.
In the 1-way sensitivity analyses, the parameters 
for absorbable pins were varied using wide ranges 
that allowed the parameters to take extreme values 
and explore their individual effect on the cost-effec-
tiveness results (0–1 for the probability of each 
event; 0–2 for the decrement OR; 0.7–1 for the QALY 
weights; £0–£1000 for the cost of revision and 
removal; £0–£300 for the cost of absorbable pins and 
complications). Only changes in the probability of 
recurrence and removal and in the impact of absorb-
able pins on QoL were found to have a meaningful 
impact on the model outcome; these are presented in 
Table 6. Absorbable pins no longer dominate but 
were still considered more cost-effective than metal-
lic fixation if their probability of recurrence was 
21% in gate 1 and gate 2 and 27% in gate 3 (com-
pared with base values of around 8% at each gate). 
However, suture fixation would be regarded as the 
most cost-effective strategy for a threshold value of 
£20 000 per QALY. Regarding the impact on QoL, 
absorbable devices would no longer dominate metal-
lic fixation if both were to have the same impact on 
QoL (OR = 1). Only if absorbable pins had a negative 
impact on the QALY weight compared with the 
standard methods (represented by a decrement OR 
higher than 1 compared with the base value of 0.474), 
Table 4 Data Used to Estimated Quality-Adjusted Life Year Weights Prior to 1991
None
Mild Pain, No 
Functional Limitation
Moderate Pain, Occasional 
Functional Limitation
Severe Pain, Frequent 
Functional Limitation Distrib
Proportions of patient in each category Dirichlet
Preoperative 0.01 0.04 0.75 0.20
Postoperative 0.67 0.25 0.07 0.01
SF-6Da description Constant only PAIN2 PAIN3, PF2 PAIN4, PF3, RL2
QALY valuation 1 0.953 0.922 0.88
Note: Distrib, parameter distribution. 
a. Only pain (PAIN), physical functioning (PF), and role limitations (RL) were considered relevant to hallux valgus (excludes social functioning, mental 
health, and vitality).
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sutures would be the most cost-effective method in 
gate 1 and gate 2. The results were insensitive to the 
probability of removal of the absorbable pins in that 
more than 85% of the devices needed to be removed 
in order for absorbable pins to be not cost-effective, 
compared with 2% assumed in gate 1 and gate 2 and 
0% reported in gate 3.
The probability that absorbable pins are the most 
cost-effective strategy increased over the 3 evalua-
tion gates, as the CEACs show in Figure 3. In 1987, 
based on a willingness to pay per QALY higher than 
£1000 per QALY, the fixation method most likely to 
be the optimal was the absorbable device, with a 
probability of more than 70%, which was quite sta-
ble among the range of potential thresholds. This 
probability increased to more than 85% and to 
around 90% for the evaluations in 1990 and 1995. 
These high probabilities of success in terms of cost-
effectiveness would have encouraged the company 
to continue with the device at each of the 3 decision 
gates. VOI analysis indicated that the most valuable 
parameter to collect further information about was 
QoL data. However, this is from a societal perspec-
tive and may not translate into the investment on 
future research that would be worthwhile for a 
company.
Late-Stage Analysis 
Health economic analyses undertaken in the late 
stage are typically designed not just to inform inter-
nal decisions but to inform external decision makers 
(e.g., health service purchasers) about the expected 
cost-effectiveness of the new technology and so to 
make the case for reimbursement of the product. 
Although preferably they would be based on evi-
dence provided by large RCTs, the need to incorpo-
rate all the relevant information in an appropriate 
way has also been argued.17 
Methods
At this stage, prior distributions for the parameters 
of interest are formed using the previously collected 
data and combined within the Bayesian framework 
with the newly available data. Parameter uncertainty 
is again explored by means of PSA, and these results 
are used to quantify the societal cost of making the 
wrong decision about which technology to fund. 
Table 6 Break-Even Points as Estimated From the One-Way Sensitivity Analyses 
One-Way Sensitivity Analysis range
Metallic (Break Even So Absorbable Do 
Not Dominate Metallic)
Sutures (Break-Even Absorbable Cost Per 
QALY >£20 000)
Absorbable pins Gate 1 Gate 2 Gate 3 Gate 1 Gate 2
Probability reoccurrence 0–1 21% 21% 27% 21% 21%
Probability removal 0–1 85% 85% 89% NA NA
Decrement OR 0–2 1 1 1.03 1.05 1.05
Note: OR, odds ratio; QALY, quality-adjusted life year.
Table 5 Deterministic Results for Mid-Stage and Late-Stage Analyses
Mid-Stage Late-Stage
Gate 1 (1987 and Earlier) Gate 2 (1988–1990) Gate 3 (1991–1995) GATE 4 (1996 Onward)
Strategy Cost QALYs Cost QALYs Cost QALYs Cost QALYs
Sutures £917 20.32 £1075 20.32 NA NA NA NA
Absorbable £989 20.52 £1148 20.52 £1494 20.64 £1694 19.32
Metallic £1386 20.33 £1610 20.33 £2141 20.49 NA NA
Standard NA NA NA NA NA NA £1688 19.30
ICERs:
Absorbable £356a £356a — £283b
Metallic Dominated Dominated Dominated NA
Note: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; NA, not applicable. 
a. ICER of absorbable pins versus sutures.
b. ICER of absorbable pins versus standard methods (include both sutures and metallic devices).
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Data
The data for the late stage analyses are reported in 
the last column of Table 2 and Table 3. We use the 
data from a small RCT conducted in 1997 where 
patients undergoing osteotomy to treat hallux valgus 
were allocated to a treatment group (absorbable 
pins) or to a control group (using standard tech-
niques, i.e., bone suture or metallic fixation).18 Since 
both standard methods were combined in the trial, 
the comparison at this stage was absorbable pins 
against both sutures and metallic devices (which are 
referred to as “standard” in the analysis). The num-
ber of interventions in the study was 39 (28 patients), 
where 17 osteotomies were stabilized with standard 
fixation and 22 were internally fixed with absorb-
able pins. 
Probabilities. In the RCT, no patients were 
reported to need a revision surgery (other than for 
the removal of metallic devices), and because of the 
different breakdown of complications in this study 
compared with previous literature, we pooled the 
data on all other complications. The small sample 
size of the trial prevented statistical analyses of the 
complications rates between the 2 groups. We used 
the data collected from the earlier analyses to form 
prior distributions of the recurrence risk and other 
complications and update those with the data from 
the trial using the following model:
r ~ Binomial(p, n)
p ~ Beta(alpha, beta)
where r is the number of events, n is the sample 
size of the trial, and p is the probability of the 
event that has a prior that follows a beta distribu-
tion where alpha and beta are computed to approx-
imate the posterior from the meta-analysis of the 
previous evidence. The WinBUGS synthesis was 
conducted with 20 000 burn-in iterations, fol-
lowed by a further 20 000 iterations for each prob-
ability, which led to the same posterior 
distributions when different initial values were 
applied. We assume the events to be independent 
of one another. 
The removal probability after standard fixation 
methods reported in this study was much lower than 
in the early literature but consistent with what was 
reported in other contemporaneous studies,19 prob-
ably because of technology changes and the inclu-
sion of suture together with metallic fixation as the 
control group. 
Costs. We applied the NHS reference costs data 
deflated to the year of interest. The 12-month cost 
for individuals with hallux valgus receiving no treat-
ment or conventional treatment was reported in a 
study in 2001,20 and it was included in the analysis 
as the cost of recurrence of the condition. 
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Figure 3 Cost-effectiveness acceptability curves and population expected value of perfect partial information at mid-stage analyses.
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Quality of life. Contrary to what was included in 
previous stages of analysis and based on the elicited 
expert opinion, the RCT found no significant differ-
ences between the 2 groups in any of the preoperative 
and postoperative radiological and clinical measures 
including pain (metatarsalgia), walking ability, foot-
wear choice, and cosmetic appearance. Therefore, the 
impact on QoL assumed in earlier analyses was no 
longer included in the model. The health-related QoL 
index for individuals undergoing hallux valgus sur-
gery was measured before and after the intervention 
in a study in 2001,20 and these values were applied to 
the recurrence and cured states, respectively.
Results
The results are presented in Table 5. The expected 
cost for absorbable pins was slightly higher than for 
standard fixation, although absorbable pins result in a 
better expected health outcome. The ICER was £283 
per QALY. The CEAC at this stage is presented in 
Figure 4. The method of fixation most likely to be cost-
effective was absorbable pins with a probability of just 
above 55% at any threshold value. This probability 
was considerably lower than the analogous probabili-
ties at earlier stages. The population-EVPI for different 
sets of parameters (cost parameters, QALY weights 
and impact on QoL, and probabilities of each event) 
shows that the information with the greatest value was 
related to the QALY weights and impact on QoL for a 
threshold value of £20 000 and £30 000 per QALY. 
DISCUSSION
We applied an iterative Bayesian approach to the 
early assessment of cost-effectiveness of a medical 
device during its development process by evaluating 
the potential cost-effectiveness of the device at 4 dif-
ferent decision points. 
Starting with simple methods such as the effec-
tiveness gap analysis or headroom estimate, the 
device appeared to be cost-effective based on the 
assumptions applied and the elicited impact on QoL 
from experts. Given this positive outcome, manufac-
turers may decide to continue with the product 
development and run a more formal analysis at this 
point, that is, synthesizing the evidence into a deci-
sion model. This required incorporating more infor-
mation in the analysis in order to populate the 
decision tree used for the evaluation. Compared 
with the headroom analysis (where the maximum 
reimbursable price for absorbable pins was esti-
mated as high as £21 306), the decision model at the 
same stage estimates absorbable pins to be cost-
effective with a probability of around 70% at a much 
lower cost of the device (£63). Therefore, the early-
stage analysis would suggest continuation of the 
technology at the realized price. The outcomes of 
the early-stage analysis and the first mid-stage evalu-
ation undertaken at the same time period in gate 1 
are not easily comparable. The differences between 
them are mainly due to the fact that the headroom 
analysis is driven by the elicited QALY weights after 
the use of absorbable and metallic fixation of 0.95 
and 0.90, respectively. However, in the decision 
model we require information on the QALY weight 
of individuals who recovered and that of individuals 
whose condition reoccurred after the surgery, which 
were derived from Table 4 using information from 
Merkel and others (1983). The resulting QALY 
weight after a successful surgery is 0.981, which 
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leads to a QALY weight of 0.991 when applying the 
decrement OR (difference from perfect health) 
derived from the elicited QALY weights for absorb-
able pins. The incremental effectiveness was there-
fore much lower than that reported in the elicitation 
exercise and provided less optimistic results. As a 
result, the probability that absorbable pins are cost-
effective at the maximum reimbursable price derived 
from the early-stage analysis (£21 306) is estimated 
to be close to zero in the mid-stage analysis. 
We populated the decision tree using information 
available in 1987, 1990, and 1995. We found that 1) 
absorbable devices were the most cost-effective strategy 
in osteotomy for a conventional cost-effectiveness 
threshold of £20 000 per QALY, 2) the parameters with 
the largest impact on model outcomes were the proba-
bility of recurrence and the impact on QoL, and 3) the 
PSA showed a high probability (between 70% and 90% 
in the first 3 gates) of the device being cost-effective 
after accounting for all the parameter uncertainty. 
At the late-stage analysis, previously collected 
data were used to form the prior distributions of 
some parameters that were updated with the evi-
dence from an RCT. Absorbable devices appeared to 
remain the most cost-effective strategy, although the 
probability after addressing uncertainty fell to just 
above 55%. The principal reasons for this drop were 
the reduced effect on QoL of absorbable pins over 
standard methods found in the RCT and the techno-
logical changes related to metallic devices that 
resulted in a reduced risk of removal of this type of 
device. The VOI analysis shows that the parameters 
for which further information would be most valu-
able were those related to the QALY weights and the 
impact of absorbable pins on QoL. 
The use of a retrospective study to illustrate the 
concepts was necessary given the elapsed time 
involved in a prospective study and the difficulty of 
access to, and publication of, a commercially sensi-
tive ongoing development. Given the retrospective 
nature of the case study analysis, the elicitation and 
application of assumptions in the early stages of the 
evaluation were the weakest part of this study. The 
results show that the believed impact on the elicited 
QoL weights and the assumptions regarding compli-
cation rates were too optimistic, compared with the 
data later available. This optimism may be a common 
occurrence in the early evaluations of new products, 
and also companies may not anticipate the technical 
progress of competitors. Furthermore, in our retro-
spective example, the elicitation could only involve a 
very crude elicitation exercise, which did not provide 
reliable data. Therefore, these assumptions and elic-
ited effects were not included in the priors at later 
stages when additional evidence became available, as 
they may have contaminated the results rather than 
adding any information. This limitation would be 
overcome in a context where the analysis is under-
taken prospectively and therefore good quality prior 
information can be properly elicited using more 
robust methods for the parameters for which there is 
no evidence. Although the elicitation methods are 
nontrivial, there is a growing body of research on how 
to elicit expert knowledge accurately and reliably.21 In 
a context of a small RCT, such as in this example, 
elicited information if based on a body of expert opin-
ion can enhance the evidence from the trials.
The inclusion of more information in the analysis 
did not reduce the uncertainty in the decision as one 
would hope but in fact did the opposite. This may be 
a common circumstance if the new data obtained do 
not confirm but instead challenge some of the previ-
ous beliefs, assumptions, or data, making the choice 
between 2 alternatives less clear as is the case in our 
example. There is also a well-documented tendency 
to underestimate uncertainty about the knowledge 
of quantitative information.22 This may generate 
reported prior distributions from expert opinion that 
are far too tight, and, therefore, new collected infor-
mation might often fall outside the error bars of the 
elicited data. This would also has consequences for 
the value of information analysis, as it may be biased 
downward if the elicited priors do not represent the 
“true uncertainty” about the parameters.23 In our 
example, the expected value of perfect partial infor-
mation for the QALY weights and the impact on QoL 
increased considerably at the late-stage analysis, 
when information from the elicited expert opinion 
was no longer included in the analysis. 
The main advantage of the proposed approach is 
that it could support internal decision making in 
order to prioritize the alternative products to be 
developed and avoid investing in a product that 
could never be cost-effective. However, as the exem-
plar product achieved commercial success anyway, 
it is difficult to prove whether such analysis, if it 
had been undertaken, would have been commer-
cially beneficial. It may have encouraged the accel-
eration of the development process or the setting of 
a higher price (subject to expectations about com-
petitive responses), or the final-stage analysis may 
have speeded an increased market penetration. 
Further research based upon a product that failed in 
the market would be valuable. 
There are potentially broader benefits related to 
the proposed approach compared with undertaking a 
late-stage analysis alone. First, introducing formally 
the cost-effectiveness criterion as a variable into the 
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product development process means that commer-
cial decisions are in line with policy requirements. 
This could support the development of more cost-
effective products that would eventually be brought 
to the market. Second, collecting and synthesizing 
data from early stages and identifying the parameters 
for which more information would be valuable when 
there is scope for further research could facilitate 
more accurate estimates in the economic evaluation 
undertaken at a late stage. Third, late-stage public 
sector economic evaluations may be costly. The 
stage-evaluation approach conducted internally 
ensures the collection of data and provision of evi-
dence, which would reduce the cost of the late-stage 
public sector economic evaluation usually under-
taken when the product is ready for market launch.
Finally, standard VOI analysis takes a societal 
perspective. Although this approach is useful for 
government agencies considering funding the devel-
opment of products, the approach is problematic in 
a commercial setting. Ideally, in this context, the 
method of VOI analysis should be adapted to inform 
the value to a company of conducting further 
research internally to reduce uncertainty and there-
fore to reduce the cost of making a wrong investment 
decision. In such case, the wrong decision would be 
to abandon (proceed with) the product when the 
eventual purchase decision is (not) to reimburse it. 
Further research on the commercial perspective in 
this context would be valuable. 
We have illustrated the potential use and the chal-
lenges involved in applying iterative economic eval-
uation to inform commercial investment decisions 
concerning the development of a new product by 
anticipating the eventual purchase decisions. The 
most influential parameters affecting the outcome of 
the decision can be identified from these early stages 
in order to direct research resources, and the uncer-
tainty of the decision can be explored. By gradually 
increasing the complexity of the techniques used in 
the evaluation, we ensure that the methods under-
taken at each stage take into account the availability 
of data and resources, in terms of both time and 
money, that characterize each development phase. 
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